We do more than research. Every day, we take on science-based health challenges in order to transform them into solutions that improve and save lives. Here are our current areas of exploration that we confidently believe will lead to discoveries.
Our BPI-002 program is based on an oral small molecule agent that increases T-cell co-stimulation. Due to its short pharmacokinetic half-life, it has the potential of managing immune-related adverse events better than biological long half-life agents like cytotoxic T-lymphocyte-associated protein 4 inhibitors in combination with programmed cell death 1 (PD-1)/programmed death ligand 1 inhibitors. In preclinical cancer models, BPI-002 has significant anticancer effects as a monotherapy and in combination with checkpoint inhibitors. Investigational new drug-enabling studies and efforts related to manufacturing and safety testing have been initiated.
Our IκB kinase (IKK) program, BPI-003, is based on a novel small molecule inhibitor of IKK, a protein kinase. IKK is involved in the survival of some tumor cells as well as in the production of a number of cytokines and growth factors that serve as survival factors for various tumors. Our IKK inhibitor has shown promising activity in multiple animal models of pancreatic cancer.
Our BPI-004 program is focused on a small molecule that induces the production of neoantigens by tumor cells, allowing tumors with no immune cells to be infiltrated by the immune system. A large proportion of human cancers do not produce antigens that are recognized by the immune system. As a result, these tumors do not respond to treatments that work through interaction with the patient’s immune response. For example, these tumors will not respond to treatment with PD-1 inhibitors. A treatment that induces the tumor cells to produce antigens has the potential to make these cancers responsive to PD-1 inhibitors.